Fluidigm Announces New Co-Marketing Program under Collaboration Agreement with Visiopharm, Offering AI-Based Image Analysis Software

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a new co-marketing program to offer Visiopharm® image analysis software for faster and more streamlined analysis of data acquired through Imaging Mass Cytometry™ (IMC™). The program is the latest phase of an ongoing collaboration between the two companies.